Investors
Agios is a biopharmaceutical company passionately committed to applying our scientific leadership in the field of cellular metabolism to transform the lives of patients with cancer and rare genetic diseases.
Stock is 
Press Release
 View printer-friendly version << Back

Agios Pharmaceuticals to Webcast Conference Call Discussing Third Quarter 2013 Financial Results on November 7, 2013

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 31, 2013-- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the fields of cancer metabolism and inborn errors of metabolism, today announced that the company will host a conference call and live audio webcast on Thursday, November 7, 2013, at 8:30 a.m. EST to report its third quarter 2013 financial results and discuss recent business activities.

In order to participate in the conference call, please dial 1-877-377-7098 (domestic) or 1-631- 291-4547 (international) and refer to conference ID 92532816. The live webcast can be accessed under "Events & Presentations" in the Investors and Media section of the company's website at www.agios.com. The archived webcast will be available on the company's website beginning approximately two hours after the event.

About Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals is focused on discovering and developing novel drugs to treat cancer and inborn errors of metabolism, or IEMs, which are a subset of orphan genetic metabolic diseases, through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has multiple first-in-class lead product candidates in cancer metabolism and IEMs in clinical and/or preclinical development. All Agios programs focus on genetically identified patient populations, leveraging our knowledge of metabolism, biology and genomics. For more information, please visit our website at www.agios.com.

Source: Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals:
Glenn Goddard
SVP Finance
investors@agios.com
or
Media Contact:
Dan Budwick, 973-271-6085
dan@purecommunicationsinc.com